Zai Lab Limited (NASDAQ:ZLAB) Insider Rafael Amado Sells 7,583 Shares

Zai Lab Limited (NASDAQ:ZLAB) insider Rafael Amado sold 7,583 shares of the business’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $26.28, for a total value of $199,281.24. Following the completion of the sale, the insider now directly owns 33,834 shares of the company’s stock, valued at approximately $889,157.52. The trade was a 18.31 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Zai Lab Stock Down 5.3 %

NASDAQ:ZLAB opened at $24.81 on Friday. The company’s 50 day moving average is $28.12 and its 200-day moving average is $23.00. Zai Lab Limited has a 12 month low of $13.48 and a 12 month high of $36.60. The firm has a market cap of $2.70 billion, a price-to-earnings ratio of -8.96 and a beta of 0.99.

Analyst Upgrades and Downgrades

Several research firms have commented on ZLAB. Cantor Fitzgerald reissued an “overweight” rating on shares of Zai Lab in a research report on Friday, October 25th. JPMorgan Chase & Co. increased their target price on shares of Zai Lab from $38.00 to $44.00 and gave the stock an “overweight” rating in a research report on Monday, October 21st.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC grew its position in shares of Zai Lab by 34.2% in the third quarter. Janus Henderson Group PLC now owns 8,760,074 shares of the company’s stock valued at $211,488,000 after purchasing an additional 2,232,507 shares during the last quarter. Wellington Management Group LLP grew its holdings in Zai Lab by 18.4% in the 3rd quarter. Wellington Management Group LLP now owns 8,436,606 shares of the company’s stock valued at $203,660,000 after buying an additional 1,312,115 shares during the last quarter. Bamco Inc. NY increased its position in Zai Lab by 6.4% in the 3rd quarter. Bamco Inc. NY now owns 1,906,520 shares of the company’s stock worth $46,023,000 after buying an additional 113,869 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Zai Lab by 26.2% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 604,153 shares of the company’s stock worth $14,584,000 after buying an additional 125,532 shares during the last quarter. Finally, TD Asset Management Inc boosted its position in shares of Zai Lab by 1.4% in the second quarter. TD Asset Management Inc now owns 221,970 shares of the company’s stock valued at $3,847,000 after acquiring an additional 3,000 shares during the period. Institutional investors own 41.65% of the company’s stock.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.